Chipscreen Biosciences
As of the edition of 20 October 2026, Chipscreen Biosciences runs 12 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 8 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tislelizumab | Ends 2036 (computed from the first US licence) | 2 |
| Tucidinostat | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Cancer: 22 trials led
- Hormones: 9 trials led
- Lungs and airways: 9 trials led